Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Authorities Stonewall Pharma’s Transparency Demands

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s pharma industry is trying to force the government to reveal the decision-making process that led it to uphold the drug rebate and price freeze there, in the hope of avoiding fresh burdens in the future.

You may also be interested in...



German Pharma Industry Cries Foul As Preliminary Evaluation Of AMNOG Suggests It Works

Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.

Rasi At The EMA: Redefining Benefit/Risk As Staggered Approvals Rise

The Executive Director of the European Medicines Agency Guido Rasi’s dual goals of increasing safety and overall accountability undoubtedly will benefit patients and industry alike, but a grueling task lies ahead.

German Parliament Considers Lowering Mandatory Drug Rebate Level

The German Upper House has proposed reducing the obligatory rebate manufacturers of original drug products must give health insurers and closing a loophole in the law on generic drug discount contracts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel